Author
By Christopher Robertson Invoking the First Amendment protection of speech, the Second Circuit today reversed a criminal conviction for a drug salesman’s promotion of a drug beyond its FDA-approved uses. The case in U.S. v.…
By Christopher Robertson New hospital safety scores were released this week, and around the country, those that scored well are crowing (see e.g., here and here). The data is provided by a nonprofit called Leapfrog…
By Christopher Robertson The Washington Post covers a new order by DC district court judge Gladys Kessler, arising out of an old RICO case brought by the federal government, requiring that the tobacco companies publish…
By Christopher Robertson The Washington Post has an extensive story about the drug and device industry’s influence on the outcomes of clinical trials, which are published in leading medical journals and which then shape the…
[Ed. Note: We’re happy to announce that after a great month of guest blogging, Chris Robertson will be joining Bill of Health as a regular contributor.] By Christopher Robertson The New York Times brings us…
By Christopher Robertson When I moved to the University of Arizona, I quickly discovered something that I’ll politely call “heterogeneity” in Institutional Review Board’s (IRB) policies and practices. All of a sudden, some of the…
By Christopher Robertson Yesterday (Friday Nov 16), U.S. District Judge Reggie Walton granted a preliminary injunction barring enforcement of the contraceptive coverage mandate that was part of the regulations implementing the Affordable Care Act (ACA).…
By Christopher Robertson Paul Gowder (Iowa Law) has shared a draft of his new article, Death and Taxes in NFIB v Sebelius. Gowder thoughtfully develops some of the themes that I gestured towards in my “Lopsided Giant”…
By Christopher Robertson Professor Elhauge‘s provocative little book, Obamacare on Trial, has many of us rethinking and revisiting the NFIB v. Sebelius decision, and I had a chance to attend the nice book talk featuring Professor…
